The JAK2_V617F mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden.

ABSTRACT: Alleviating symptom burden in patients with myeloproliferative neoplasms (MPNs) is imperative to achieving optimal management. Research remains to elucidate the relationship between the JAK2_V617F (Janus kinase 2) mutation present in many MPN patients, and the symptomatology they experience. This retrospective study analysed data collected from MPN patients included in the Myeloproliferative Neoplasms: An In-depth Case-Control (MOSAICC) pilot study. The MPN Symptom Assessment Form was administered, and median symptom scores were compared between JAK2_V617F-positive and JAK2_V617F-negative groups. Multivariate logistic regression analysis adjusted for confounding variables. Overall, 106 MPN patients participated: 65.1% were JAK2

SUBMITTER: Orbell LY 

PROVIDER: S-EPMC10660120 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature